Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Clinical Significance of Circulating Tumour Cells in Resectable Lung Cancer Patients

NCT05619562 is registered in ClinicalTrials.gov with The Institute of Molecular and Translational Medicine, Czech Republic as lead sponsor.

NCT NCT05619562
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05619562 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Clinical Significance of Circulating Tumour Cells in Resectable Lung Cancer Patients
Lead sponsor
The Institute of Molecular and Translational Medicine, Czech Republic
Phase
Observational
Overall status
Completed
Start date
January 31, 2009
Completion date
December 31, 2015
Enrollment
166 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

circulating tumor cell, non small cell lung cancer